Clinical Trial Update: Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of IBI362 in overweight or obese subjects has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overweight or Obesity

Drugs mentioned

• IBI362

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Overweight or Obesity | Phase 1, Phase 2 | Status: COMPLETED